{
  "cik": 2023658,
  "cik_padded": "0002023658",
  "entityName": "Bicara Therapeutics Inc.",
  "fiscal_years": [
    {
      "accn": "0001628280-26-022010",
      "filed": "2026-03-30",
      "fiscal_year": 2025,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 280000.0,
        "cash": 96685000.0,
        "eps_diluted": -2.52,
        "free_cash_flow": -107114000.0,
        "net_income": -137950000.0,
        "operating_cash_flow": -106834000.0,
        "operating_income": -155604000.0,
        "stockholders_equity": 401452000.0,
        "total_assets": 430994000.0,
        "total_liabilities": 29542000.0
      },
      "period_end": "2025-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.0735878760100834,
        "roa_avg2y": -0.2932018406146718,
        "roa_period_end": -0.32007406135584254,
        "roe_avg2y": -0.3088454731582052,
        "roe_period_end": -0.3436276316969401
      }
    },
    {
      "accn": "0001628280-26-022010",
      "filed": "2026-03-30",
      "fiscal_year": 2024,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 71000.0,
        "cash": 489711000.0,
        "eps_diluted": -4.05,
        "free_cash_flow": -74822000.0,
        "net_income": -67995000.0,
        "operating_cash_flow": -74751000.0,
        "operating_income": -82389000.0,
        "stockholders_equity": 491875000.0,
        "total_assets": 509996000.0,
        "total_liabilities": 18121000.0
      },
      "period_end": "2024-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.03684066073697586,
        "roa_avg2y": -0.1827876630760587,
        "roa_period_end": -0.13332457509470663,
        "roe_avg2y": -0.39634981609182,
        "roe_period_end": -0.13823634053367218
      }
    },
    {
      "accn": "0001628280-26-022010",
      "filed": "2026-03-30",
      "fiscal_year": 2023,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 586000.0,
        "cash": 230440000.0,
        "eps_diluted": -89.61,
        "free_cash_flow": -46214000.0,
        "net_income": -51985000.0,
        "operating_cash_flow": -45628000.0,
        "operating_income": -39889000.0,
        "stockholders_equity": -148769000.0,
        "total_assets": 233982000.0,
        "total_liabilities": 15474000.0
      },
      "period_end": "2023-12-31",
      "ratio_units": {
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio"
      },
      "ratios": {
        "roa_period_end": -0.22217521005889343,
        "roe_avg2y": 0.4199586382951222
      }
    },
    {
      "accn": "0002023658-25-000012",
      "filed": "2025-03-27",
      "fiscal_year": 2022,
      "form": "10-K",
      "fundamental_units": {
        "stockholders_equity": "USD"
      },
      "fundamentals": {
        "stockholders_equity": -98803000.0
      },
      "period_end": "2022-12-31",
      "ratios": {}
    }
  ],
  "latest_filing": {
    "accn": "0001628280-26-022010",
    "filed": "2026-03-30",
    "form": "10-K"
  },
  "note": "Static grepcent export of verified SEC companyfacts-derived values. Monetary values are raw reported units from grepcent's resolved facts; no scaling and no FX conversion. Capex, dividends, and buybacks are reported as positive outflow magnitudes. ROE/ROA include both period-end basis (site-consistent) and average-of-two-years basis where the prior-year denominator exists.",
  "schema_version": "1",
  "sic": "2834",
  "sic_description": "Pharmaceutical Preparations",
  "source_urls": {
    "sec_companyfacts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0002023658.json",
    "sec_submissions": "https://data.sec.gov/submissions/CIK0002023658.json"
  },
  "ticker": "BCAX"
}